Proprotein Convertase Subtilisin/Kexin Type 9 Market

Request Discount

Proprotein Convertase Subtilisin/Kexin Type 9 Market (Product - SX-PCK9, K-312, DCRPCSK-9, LY3015014, and Others; Application - Cardiovascular Disease, Homozygous Familial Hypercholesterolemia, Liver Disease, Metabolic Syndrome, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2027

  • Published : February, 2022

  • Rep Id : HC08745

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the proprotein convertase subtilisin/kexin type 9 market provides in-depth analysis of segments and sub-segments in the global as well as regional proprotein convertase subtilisin/kexin type 9 market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional proprotein convertase subtilisin/kexin type 9 market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global proprotein convertase subtilisin/kexin type 9 market. According to the report, the global proprotein convertase subtilisin/kexin type 9 market is projected to reach USD 4 billion by 2027 from USD 2 billion in 2021, growing at a CAGR of 9% over the forecast period of 2021-2027.

 

Market Insight

The new proprotein convertase subtilisin/Kexin type 9 inhibitors (PCSK9i) are LDL-cholesterol (LDLc) lowering drugs. The PCSK9i available on the market (alirocumab [Praluent®] and evolocumab [Repatha®]) are 100% human monoclonal antibodies that selectively bind in plasma to PCSK9, and they prevent the latter from binding to the low-density lipoprotein (LDL) receptor. Proprotein Convertase Subtilisin-like Kexin type 9 (PCSK9) is discovered serine protease that destroys LDLR in the liver and controls the levels of LDL in plasma. They play a vital role in the regulation of cholesterol homeostasis. They are a class of medications for patients suffering from familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease that require additional lipid-lowering beyond dietary measures and statin use. The medication is costly so payers are less. Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are drugs that appear promising as a novel agent for LDL-C reduction after being tested in several clinical trials.

 

The increasing frequency of atherosclerotic cardiovascular diseases and familial hypercholesterolemia is expected to drive market growth in the upcoming years. Moreover, the immobile lifestyle leading to a high frequency of cardiovascular diseases and increasing awareness of the treatment options are expected to drive the market. The high cost of PCSK9 inhibitors is likely to hamper market growth. Various technological advancements, such as the development of novel drug classes will create opportunities for the market to grow.

 

Among the regions, North America accounted for the largest share in the global Proprotein Convertase Subtilisin/Kexin Type 9 Market. Due to the high prevalence of cardiovascular diseases and atherosclerosis, highly-developed healthcare infrastructure, and key developments by the major market players, growing R&D approvals will dominate its growth in this region in the forecasting years. However, the Asia Pacific region is anticipated to grow at the highest rate in the global Proprotein Convertase Subtilisin/Kexin Type 9 Market over the forecast period. The growth is attributed to the increasing demand for healthy food products in emerging markets. Highly developing countries in this region are improving health care infrastructure and increasing awareness related to heart disease treatment. Moreover, the surge in the geriatric population with heart problems due to sedentary lifestyles is likely to propel the market in the region.

 


Proprotein Convertase Subtilisin/Kexin Type 9 Market


Segment Covered

The report on the global proprotein convertase subtilisin/kexin type 9 market covers segments such as product, and application. On the basis of product, the sub-markets include SX-PCK9, K-312, DCRPCSK-9, LY3015014, and others. On the basis of application, the sub-markets include cardiovascular disease, homozygous familial hypercholesterolemia, liver disease, metabolic syndrome, and others.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Pfizer Inc, Novartis AG, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Ensemble Therapeutics Corp, The Medicines Company, Regeneron Pharmaceuticals In, AFFiRiS AG, BioLingus AG, Catabasis Pharmaceuticals Inc, and Bioleaders Corp.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the proprotein convertase subtilisin/kexin type 9 market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount